Sedana Medical AB (publ), Year-end report, 2019
Regulatory
Another strong quarter with increased sales growth
Sedana Medical donates AnaConDa to hospitals in Wuhan, China
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is donating the medical device AnaConDa and accessories for anti-epidemic use and evaluation of the effects of inhalation sedation with AnaConDa on severely ill Corona v…
Sedana Medical establishes sales organization in Benelux
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has set up its own direct sales organization in Benelux, in line with the strategy of being represented in several European markets in order to have well-established net…
Sedana Medical receives approval for AnaConDa in Mexico
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has obtained market approval for AnaConDa in Mexico. Sedana Medical's Mexican distributor Goba will begin sales work in the next few months and in parallel Sedana will e…
Sedana Medical’s CEO divests shares – remains committed and long-term shareholder
Non-regulatory
Christer Ahlberg, CEO of Sedana Medical AB, has informed the Company that he has sold 30 000 shares in Sedana Medical, representing approximately 0.1% of total outstanding shares and 13.0% of his total shareholding in the Company, and that he has ent…
Last patient included in Sedana Medical's pivotal IsoConDa study
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the last patient has now been included in the pivotal IsoConDa study. Thus, all 300 patients have been included and the study is expected to show top-line results during Q2 2020.
Sedana Medical supports isoflurane sedation study for reduction of delirium
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is funding a large French multicenter study with isoflurane – the substance in the company´s drug candidate IsoConDa – delivered by the company’s medical device AnaConDa…
Sedana Medical AB (publ), Interim report Q3, 2019
Regulatory
Strong sales growth and good progress towards registration
Sedana Medical’s board member Michael Ryan resigns
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that Michael Ryan is retiring and therefore is resigning from the company’s board of directors.
Sedana Medical adjusts and clarifies its long-term financial targets
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company will no longer communicate a profit target for the period until registration of IsoConDa in Europe. It also clarifies the sales target of SEK 500 million three years aft…
Sedana Medical’s nomination committee appointed
Non-regulatory
Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 28, 2019, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes t…
Sedana Medical is co-funding AnaConDa study on lung protection
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is co-financing the world's largest multicenter study with AnaConDa in France. The primary purpose of the study is to show that inhaled sedation with AnaConDa has lung p…
Sedana Medical AB (publ) has completed a directed new share issue of 2,896,000 shares, raising proceeds of SEK 375 million
Regulatory
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLI…
Sedana Medical AB (publ) prepares for listing on the Nasdaq Stockholm main market
Regulatory
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLI…
Sedana Medical AB (publ) intends to undertake a directed new share issue
Regulatory
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLI…
Sedana Medical's AnaConDa approved to be used in children
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company's medical device AnaConDa, for the administration of volatile anesthetics for sedation of mechanically ventilated intensive care patients, has received approval for use…
Sedana Medical AB (publ), Interim report Q2, 2019
Regulatory
Strategic partnership in Asia and continued strong growth
Sedana Medical enters India – signs Indian distributor
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced a distribution agreement with the Indian distributor Hansraj Nayyar Medical. Sales will commence in the fall and a registration process will start in parallel. Hansraj Nayyar has committ…
The grant recipients of the Sedana Medical Research Foundation 2019 presented
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced the recipients of the Sedana Medical Research Foundation (SMRF) grant 2019. Three research projects will receive funding from SMRF 2019 covering the area of inhaled sedation in the inten…
Sedana Medical enters China – signs with Chinese distributor
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced a 10-year exclusive distribution agreement with the Chinese distributor Kyuan Xinhai Medical, a subsidiary of partly state-owned Shanghai Pharma, the second largest life science company…